CAS 3110124-60-9

Fórmula: C59H90N12O19

InChI: InChI=1S/C59H90N12O19/c60-20-22-61-23-24-62-48(72)17-15-46(57(86)87)70-29-25-68(36-51(76)77)27-31-71(32-28-69(26-30-70)37-52(78)79)47(58(88)89)16-18-49(73)64-35-38-8-12-41(13-9-38)53(80)65-45(34-39-10-11-40-5-1-2-6-42(40)33-39)54(81)63-21-4-3-7-43(55(82)83)66-59(90)67-44(56(84)85)14-19-50(74)75/h1-2,5-6,10-11,33,38,41,43-47,61H,3-4,7-9,12-32,34-37,60H2,(H,62,72)(H,63,81)(H,64,73)(H,65,80)(H,74,75)(H,76,77)(H,78,79)(H,82,83)(H,84,85)(H,86,87)(H,88,89)(H2,66,67,90)/t38?,41?,43-,44-,45-,46?,47?/m0/s1

Clave InChI: BDTGBTUYXGCHTF-VKOWTPDASA-N

SMILES: C1CC(CCC1CNC(=O)CCC(C(=O)O)N2CCN(CCN(CCN(CC2)CC(=O)O)C(CCC(=O)NCCNCCN)C(=O)O)CC(=O)O)C(=O)N[C@@H](CC3=CC4=CC=CC=C4C=C3)C(=O)NCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O

PDI2

CAS: 3110124-60-9

PDI2 (PSMA-DOTA-PEI2) is a ligand for prostate-specific membrane antigen (PSMA) that functions as a tumor retention agent, a reducer of renal uptake, an imaging agent, and an antitumor agent for SPECT diagnostic imaging and radiotherapy. It specifically binds to PSMA on prostate cancer cells and enters cells through clathrin-dependent endocytosis, resulting in higher tumor retention and reduced renal uptake. PDI2 is applicable in research involving prostate cancer and castration-resistant metastatic prostate cancer.

Fórmula: C₅₉H₉₀N₁₂O₁₉

Peso molecular: 1271.41

Ref: TM-TP4364